Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS -0.33%77 PEG Ratio is 1.48 as of Jul. 18, 2026, which is 78% above its 10-year median of 0.83. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 93 Biotechnology companies, Arterra Bioscience SpA ranks better than 55.91% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Arterra Bioscience SpA's PEG Ratio or its related term are showing as below:
MIL:ARBS'
s PEG Ratio Range Over the Past 10 Years
Min: 0.43 Med: 0.83 Max: 1.69
Current: 1.48
During the past 9 years, Arterra Bioscience SpA's highest PEG Ratio was 1.69. The lowest was 0.43. And the median was 0.83.
MIL:ARBS's PEG Ratio is ranked better than 55.91% of 93
companies
in the Biotechnology industry
Industry Median: 1.99
vs MIL:ARBS: 1.48
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Arterra Bioscience SpA (MIL:ARBS) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Arterra Bioscience SpA (MIL:ARBS) has a PEG Ratio of 1.48 as of Jul. 18, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Arterra Bioscience SpA and its competitors. This is 78% above median its historical median of 0.83. Over the past decade, Arterra Bioscience SpA's PEG Ratio has ranged from 0.43 to 1.69. According to the industry distribution chart, Arterra Bioscience SpA ranks #41 out of 93 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Arterra Bioscience SpA's PEG Ratio too high?
Arterra Bioscience SpA's current PEG Ratio of 1.48 is 78% above median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 1.69. The Biotechnology industry median PEG Ratio is 1.99. Arterra Bioscience SpA's value of 1.48 is 25.6% below this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #41 out of 93 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #41 out of 93 companies for PEG Ratio. This puts Arterra Bioscience SpA in the upper half of its industry. The industry median PEG Ratio is 1.99. Arterra Bioscience SpA's value of 1.48 is 25.6% below this benchmark. Historically, Arterra Bioscience SpA's own PEG Ratio has ranged from 0.43 to 1.69 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 1.99, Arterra Bioscience SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.99, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current PEG Ratio of 1.48 is 25.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current PEG Ratio is 1.48, which is 78% above median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current PEG Ratio is 1.48, which is 78% above median its 10-year median of 0.83 and 25.6% below the Biotechnology industry median of 1.99. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current PEG Ratio is 1.48 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
PEG Ratio: 1.48 (78% above median its 10-year median of 0.83)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
Industry Position: 25.6% below the Biotechnology median (#41 of 93)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
